Nass Valley Gateway Ltd. (CSE:NVG) (FR:3NVN)  is pleased to announce that, on March 22, 2018,  it executed the Definitive Acquisition and Share Exchange Agreement with Advanced Bioceutical Limited, a privately owned Limited Liability Company incorporated under the Laws of New Jersey. Under the terms of the agreement ABL and its wholly owned subsidiary Pro-Thotics Technology Inc. a New York private corporation, will become wholly owned subsidiaries of Nass Valley as the “Resulting Issuer”. The DASE-Agr constitutes a valid and legally binding agreement, enforceable against the Parties, in accordance with its respective terms,

ABL negotiated the 100% acquisition of PTI in 2017 which is a company engaged in the sale of Durable Medical Equipment with principal operations in New York, New Jersey and Florida. Since its inception in 1988, PTI has been one of the Northeast’s premier supplier specializing in orthotics and prosthetics for those in need of pain relief. PTI has a strong balance sheet and will expand its current DME business nationwide into areas of the U.S. not currently served by PTI as well as expand its business through the strategic acquisition of related companies. During PTI’s more than 25-year history, it has served over 200,000 patients located throughout the U.S. and Puerto Rico (the PTI-Business”), and provided relief from pain and medical issues through its Business.

ABL is focusing on expanding upon this pain relief concept, and will aggressively continue entering the Cannabidiol with zero THC content for internal and external use including CBD infused skin, bath, and body care products (the “ABL-Business”). In conjunction with the ABL-Business, it plans to horizontally integrate into an exciting new area for pain and health relief; CBD and related products. The markets for CBD products are growing at an exponential pace and ABL as subsidiary of NVG may also entertain partnerships with companies engaged in the production and manufacturing of products related to its business.

With its operations, presently conducted by PTI, in New York, New Jersey and Florida and its existing national marketing and advertising campaigns, ABL has action plans to establish inhouse manufactured CBD products, CBD infused skin, bath, and body care products to the U.S.

On the Effective-Date the owners of ABL and PTI will transfer to Nass Valley as the Resulting Issuer an aggregate of 100% (one hundred percent) of their ownership interest, and Nass Valley shall issue an aggregate of 89.27 % of fully paid and nonassessable common shares of  the Resulting Issuer’s shares (the “Acquisition-Shares”) in exchange for 100 % of the ownership interest of ABL and PTI.

The Parties agreed not to change the name of the Company after the approval of the transaction. It was further agreed that Mr. Dieter Peter will be the Chairman of Nass Valley, John Affenita, the founder of ProThotics Inc and an ABC and BOC Orthotist and Prosthetist, serving the O&P field for 20 years will become the Company’s  CEO and Dr. Samuel Alawieh, a Pharmacologist and highly respected scientist with significant experience in many aspects of CBD R&D,  has agreed to become COO of Nass Valley Gateway.

The proposed transaction is considered a Reversed Take Over under the rules of the CSE and requires the approval of the disclosure document (the 2A Listing Statement). The Company has obtained the written approval and consent of 54.75% from the required minimum of five registered shareholders pending the approval of the transaction by the CSE.

Dieter Peter, President & CEO, commented: “This transaction will place Nass Valley in a strong strategic position with a tremendous upside potential. I am especially delighted that ABL’s and PTI’s young and experienced management team, Mr. Gregory Vax and Mr. Michael Racaniello as major shareholders of the resulting issuer, have agreed to join Nass Valley’s future management and Board of Directors and also remain as executive managers and driving forces with ABL and PTI”.